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Antiinflammatory Therapies for Cystic Fibrosis:  
Past, Present, and Future
William A. Prescott, Jr., Pharm.D., and Cary E. Johnson, Pharm.D.
Inflammation is a major component of the vicious cycle characterizing cystic
fibrosis pulmonary disease.  If untreated, this inflammatory process
irreversibly damages the airways, leading to bronchiectasis and ultimately
respiratory failure.  Antiinflammatory drugs for cystic fibrosis lung disease
appear to have beneficial effects on disease parameters.  These agents include
oral corticosteroids and ibuprofen, as well as azithromycin, which, in addition
to its antimicrobial effects, also possesses antiinflammatory properties.
Inhaled corticosteroids, colchicine, methotrexate, montelukast, pentoxifylline,
nutritional supplements, and protease replacement have not had a significant
impact on the disease.  Therapy with oral corticosteroids, ibuprofen, and fish
oil is limited by adverse effects.  Azithromycin appears to be safe and effective,
and is thus the most promising antiinflammatory therapy available for
patients with cystic fibrosis.  Pharmacologic therapy with antiinflammatory
agents should be started early in the disease course, before extensive
irreversible lung damage has occurred.
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Conclusion
Cystic fibrosis is the most common lethal,
genetically inherited disorder among Caucasians.1
The clinical features of cystic fibrosis occur as a
result of mutations in the cystic fibrosis trans-
membrane conductance regulator gene.2
Consequently, the cystic fibrosis airway is exposed
to a vicious cycle of obstruction, infection, and
inflammation, all intimately linked.3 Airway
inflammation begins early in the disease course,
with notable neutrophil infiltration present in
infants as young as 4 weeks.4–11 The inflammatory
process persists throughout the patient’s life and,
if left unchecked, irreversibly damages the
airways, leading to bronchiectasis and progressive
decline in lung function.10 Pulmonary disease
accounts for most of the morbidity and mortality
in patients with cystic fibrosis.  Therefore,
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interrupting this cycle with antiinflammatory
agents may slow disease progression, improve
quality of life, and delay respiratory failure.12
However, less than 50% of pulmonary practitioners
prescribe specific antiinflammatory agents, and
only 25% of patients with cystic fibrosis receive
such therapy.13
The safety and efficacy of numerous anti-
inflammatory therapies have been studied for
treatment of cystic fibrosis.  Several agents have
proved beneficial, particularly in younger patients
with mild disease.  However, safety concerns
have limited the utility of certain drugs.
Characteristics of Pulmonary Inflammation in
Cystic Fibrosis
Inflammation plays a pivotal role in the pro-
gression of lung destruction in patients with
cystic fibrosis.  The cystic fibrosis airway is
characterized by persistent infiltration of vast
numbers of neutrophils which, when present in
excess, produce more harm than good (Figure
1).1, 3, 4, 6, 8, 9, 11, 14–24 Bacterial infection and
continuing colonization are the primary stimuli
for inflammation in the cystic fibrosis airway.1
However, pulmonary inflammation has been
observed in young children without identifiable
infection.4, 6, 8, 11 If these children were truly
without infection, one might speculate that the
lack of functional cystic fibrosis transmembrane
conductance regulator in the epithelial lining of
the cystic fibrosis lung may contribute to the
inflammatory process.23 Regardless of whether
infection precedes or supersedes inflammation,
the two become closely integrated in cystic
fibrosis lung disease.24
Therapies with Proven Antiinflammatory
Effects
Corticosteroids
The therapeutic efficacy and safety of several
oral and inhaled corticosteroids have been
evaluated in children with cystic fibrosis, but the
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Figure 1. Pathophysiology of cystic fibrosis airway inflammation and potential targets of antiinflammatory therapy.  The
inflammatory process is initiated through interaction of the epithelium with bacteria or bacterial products.  Then interleukin
(IL)-8, IL-6, and possibly granulocyte-macrophage colony-stimulating factor (GM-CSF) are produced directly and indirectly
through stimulated macrophage production of IL-1b and tumor necrosis factor (TNF)-a. The latter two inflammatory
mediators stimulate the epithelium to produce IL-8, IL-6, and GM-CSF in excess.  In addition, concentration of the
antiinflammatory cytokine IL-10 is reduced in the cystic fibrosis airway, eliminating the inhibitory effect on production of IL-8
and TNF-a. The IL-8 recruits neutrophils into the airway, which subsequently release neutrophil elastase and additional IL-8
and leukotriene B4, leading to further neutrophil influx.  Neutrophils release large amounts of oxidants and proteases, which
subsequently overwhelm the deficient antioxidant and dysfunctional antiprotease defenses of the cystic fibrosis airway, leading
to direct tissue damage.  In addition, neutrophil elastase, a major protease in the cystic fibrosis lung, may indirectly cause harm
to the epithelium by increasing airway obstruction, contributing to the persistence of infection and promoting the generation of
chemoattractants.  (From references 1, 3, 4, 6, 8, 9, 11, 14–24.)
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precise mechanism through which these agents
control inflammation and affect cystic fibrosis
pulmonary disease has not been elucidated.
Investigators have proposed that the antiinflam-
matory actions of corticosteroids in cystic fibrosis
are mediated through inhibition of interleukin
(IL)-1a and IL-2 receptor expression.25 Serum
immunoglobulin G (IgG) concentrations are also
significantly decreased with systemic cortico-
steroid therapy.  This effect may reduce immune
complex formation and complement activation,
thereby diminishing lung damage.
Oral
Prednisone and prednisolone are oral gluco-
corticoids with potent antiinflammatory effects.
Prednisone has effectively controlled the inflam-
mation of cystic fibrosis pulmonary disease;
however, safety concerns limit its use for long-
term treatment in children with the disease.25–28
The benefits of oral prednisone on morbidity
and progression of lung disease in children with
cystic fibrosis was first reported in a 4-year
prospective, randomized, double-blind, placebo-
controlled trial of 45 patients aged 1–12 years
with mild-to-moderate cystic fibrosis lung
disease.26 Of these patients, 24 (mean age 6.3
yrs) were randomly allocated to placebo, and 21
(mean age 6.7 yrs) to treatment with prednisone
2 mg/kg, maximum 60 mg, every other day.
After 4 years, the prednisone-treated group
exhibited significantly higher values than the
placebo group with respect to vital capacity
(p<0.01), peak expiratory flow rate (p<0.005),
and forced expiratory volume in 1 second (FEV1)
(p<0.005).  In the prednisone group, five (24%)
patients required nine hospital admissions for
cystic fibrosis–related pulmonary disease; in the
placebo group, 10 (42%) patients required 35
admissions (p<0.001).  Gains in height (p<0.025)
and weight (p<0.005) were significantly better in
the treatment versus placebo group at the
conclusion of the study.
To confirm the outcomes reported in the first
trial, a second, larger, prospective, double-blind,
placebo-controlled study was conducted.27 A
total of 285 patients aged 6–14 years (mean 9.5
yrs) with clinically stable cystic fibrosis and a
ratio of FEV1:forced vital capacity (FVC) greater
than 60% were equally stratified in a randomized
manner to either placebo or alternate-day
prednisone 1 mg/kg (low dose) or 2 mg/kg (high
dose, maximum 60 mg).  The study was
discontinued prematurely in the high- and low-
dose groups after 2 and 3 years, respectively,
secondary to unacceptable adverse effects.
Predicted FVC was greater in patients receiving
prednisone 1 mg/kg (p<0.0001) or 2 mg/kg
(p<0.01) than in those receiving placebo.  No
significant difference in effect was observed
between the two prednisone-treated groups
(p>0.21).  In the 1-mg/kg group, improvement in
FVC was first noted at 6 months, plateaued
thereafter, and was sustained for the rest of the
study period (p<0.0025).  Mean predicted FEV1
declined to a significantly lesser extent in the 1-
mg/kg group than in the placebo group (p<0.02).
Hospitalization rates and length of stay,
Shwachman score, Brasfield score, and peak
expiratory flow rate were not significantly
different between the prednisone and placebo
groups.
In a follow-up study assessing the long-term
effects of prednisone, the improvement in
pulmonary function observed in patients treated
with alternate-day prednisone 1 mg/kg was no
longer present 6–7 years after therapy was
discontinued.29 In fact, the 13.5% decline in
FEV1 in the low-dose prednisone group during
the follow-up period was 3 times greater than the
4.5% decline in the placebo patients.  The weight
of the prednisone-treated children declined to
baseline weight within 1–2 years after treatment
discontinuation.
Although effective, the utility of corticosteroids
in the treatment of cystic fibrosis pulmonary
disease is limited by long-term safety concerns.27, 28
An early study suggested that therapy with oral
prednisone in children with cystic fibrosis would
not produce significant adverse effects.26
However, better-powered studies concluded that
long-term treatment with corticosteroids was
associated with significant risks.27, 28 Glucose
intolerance, cataract formation, multiple bone
fractures secondary to osteoporosis or osteopenia,
cushingoid effects, and anorexia nervosa
occurred in a dose-dependent fashion.27, 28, 30 The
percentage of patients colonized with Pseudomonas
aeruginosa increased from baseline when pred-
nisone 1 mg/kg (p<0.01) and 2 mg/kg (p<0.05)
every other day were given.27 Prednisone 2
mg/kg every other day for more than 6 months or
1 mg/kg every other day for more than 24
months was associated with substantial negative
effects on growth.27–29
Catch-up growth occurs in most children, both
boys and girls, 2–3 years after discontinuation of
prednisone therapy.29 However, growth impair-
ment among prepubertal boys, most prominently
those aged 6–8 years, persists for 10 years after
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treatment with prolonged alternate-day prednisone.
The final predicted height in this patient
subgroup is significantly reduced (p=0.02).  The
risk of corticosteroid-induced adverse effects is
greater during concomitant therapy with itra-
conazole and corticosteroids since itraconazole is
a potent inhibitor of corticosteroid metabolism.31,
32 When corticosteroids and itraconazole are
administered concomitantly to treat allergic
bronchopulmonary aspergillosis, monitoring
patients for symptoms suggestive of drug-related
adverse events is indicated.
In children with cystic fibrosis, treatment with
prednisone improves pulmonary function.26, 27
However, given the short-lived benefits and
serious adverse effects, prolonged prednisone
therapy for suppression of inflammation cannot
be recommended for children with cystic
fibrosis.27–32 When indicated, prednisone should
be administered in the lowest effective dose for a
limited time.
Inhaled
Inhaled corticosteroids are better tolerated and
produce fewer adverse effects than systemically
administered dosage forms.33 Of the five available
inhalation corticosteroids, beclomethasone,
budesonide, and fluticasone have been evaluated
in children with cystic fibrosis.34–39
Although one uncontrolled study suggested
that inhaled corticosteroids might modulate
neutrophil influx into the cystic fibrosis airway,
mitigation of pulmonary inflammation has not
been observed in placebo-controlled trials.34, 37–40
Inhaled corticosteroids may attenuate bronchial
hyperresponsiveness in patients with cystic
fibrosis and may improve cough and dyspnea.35, 37
However, in six controlled studies involving a
total of 191 patients aged 4 years or older, no
clinically or statistically significant benefit in
FEV1 or FVC was observed (Table 1).34–39
In clinical trials involving children and adults
with cystic fibrosis, treatment with inhaled
corticosteroids was well tolerated for up to 20
weeks.34, 35, 37–39 Whereas an apparent increase in
P. aeruginosa colonization in patients with cystic
fibrosis was observed incidentally in one small
study,35 no significant difference was reported in
two separate controlled trials.40, 41 Whereas long-
term studies assessing the effect of inhaled
corticosteroids on growth are lacking for children
with cystic fibrosis, final predicted height and
bone mineral density are generally attained in
this pediatric population.33, 42
Adrenocorticotropic hormone suppression tests
in patients with cystic fibrosis have indicated
little or no systemic effect of inhaled cortico-
steroids on the adrenal axis.37, 40 However,
Cushing’s syndrome and complete suppression of
endogenous glucocorticoid secretion have
occurred with administration of inhaled
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Table 1.  Studies of Inhaled Corticosteroid Therapy in Patients with Cystic Fibrosis
Age Range, Treatment Sputum Inflammatory Change in
No. of Mean, Median Drug and Dosage Duration Marker Improvement FEV1 and FVC
Study Design Patients (yrs) (µg/day) (wks) from Baseline vs Placebo
R, DB, PC34 13 4–29, Beclomethasone 400 16 NSa FVC: NSa
NR, 14
R, DB, CO, PC35 12 16–45, Budesonide 1600 6 NA FEV1: NSa
27, NR FVC: NSa
R, PC36 25 6–28, Beclomethasone 1500 4 NA FEV1: NSa
20, NR FVC: NSa
R, DB, PC37 30 NR, Budesonide 1600 9–20 NSa FEV1: NSa
20, NR FVC: NSa
R, DB, CO, PC38 23 7–17, Fluticasone 400 6 NSa FEV1: NSa
10, NR FVC: NSa
R, OL, PC39 12 16–38, Fluticasone 1000 3 NSc FEV1: NSb
NR, 26 FVC: NSc
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; R = randomized; DB = double-blind; PC = placebo-controlled; CO =
crossover; OL = open-label; NR = not reported; NA = safety data not assessed; NS = not significant.
No significant differences were observed in adverse drug reactions for study drug compared with placebo in all studies except reference 36, in
which adverse events were not assessed.
ap>0.05.
bp>0.1.
cp>0.2.
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budesonide combined with itraconazole.43, 44
This effect is attributed to inhibition of
budesonide metabolism by itraconazole by the
cytochrome P450 3A enzyme system.  Routine
monitoring for adrenal insufficiency is indicated
when inhaled corticosteroids and itraconazole are
concomitantly administered.
Delivery of aerosolized agents to the lungs,
which averages 10–40% of total drug delivered, is
dependent on the severity of lung disease and the
specific delivery device and technique used.33, 42
In patients with cystic fibrosis, the fraction of the
dose ultimately reaching the site of the most
severe inflammation may be poor given the
viscous, mucus-lined epithelium through which
it must pass.  In children, the drug may never reach
its primary site of action, which may account for
the lack of efficacy demonstrated by inhaled
corticosteroids in controlled clinical trials.
In theory, inhaled corticosteroids are a novel
approach—administering a potent antiinflam-
matory agent directly to the disease site—to
treating pulmonary inflammation in patients with
cystic fibrosis.  Although potentially safe, studies
have failed to demonstrate any benefit after
treatment with these drugs in children with
cystic fibrosis.  Thus, evidence-based medicine
suggests that further studies are necessary before
routine treatment with inhaled corticosteroids
can be recommended.
Ibuprofen
Ibuprofen is an oral nonsteroidal antiinflam-
matory drug commonly used in children to treat
acute pain and fever.45 The recommended anti-
pyretic and analgesic dosage is 5–10 mg/kg 3–4
times/day. In one study, ibuprofen 20–30 mg/kg
twice/day had beneficial effects on both
pulmonary function and nutrition in children
with cystic fibrosis.46 Based on these results, the
Cystic Fibrosis Foundation has advocated
ibuprofen as an antiinflammatory agent for
treating patients aged 5 years or older with cystic
fibrosis whose predicted FEV1 is 60% or greater.47
Despite reported benefits in children aged 5–13
years, less than 10% of patients with cystic
fibrosis in the United States are treated with high-
dose ibuprofen.13 The percentage of children
receiving ibuprofen may be low due to the need
for therapeutic drug monitoring and concerns
regarding the clinical safety and tolerability of
this agent.
Ibuprofen is an inhibitor of cyclooxygenase
and, at high doses, lipoxygenase.  Through
inhibition of the lipoxygenase pathway, leuko-
triene B4 production is mitigated, and neutrophil
migration and function are impaired.48–59 The
antiinflammatory effects of ibuprofen in patients
with cystic fibrosis occur  when peak plasma
concentration exceeds 50 µg/ml.59 Concentrations
below this threshold result in a paradoxical
increase in inflammation.56–60 This proinflam-
matory effect is believed to occur as a result of
substrate shunting from the cyclooxygenase to
the lipoxygenase pathway.59 Therefore, with
plasma concentrations less than 50 µg/ml,
ibuprofen may hasten cystic fibrosis lung
deterioration.
In children with cystic fibrosis, ibuprofen peak
plasma concentration and area under the concen-
tration-time curve are decreased;  however, the
apparent volume of distribution and clearance are
significantly increased.61 As the pharmaco-
kinetics of ibuprofen are dependent on the dose
and dosage form used and on the patient’s body
weight and fasted or fed state, significant
variability occurs among individual patients with
cystic fibrosis.61–63 In view of ibuprofen’s narrow
therapeutic window, and the significant inter-
patient pharmacokinetic variability, therapeutic
drug concentration monitoring is necessary.46
Ibuprofen is most commonly given in tablet
form.  Children often cannot swallow tablets;
thus, suspension and chewable tablet formulations
are attractive alternatives.  The suspension form
is absorbed most rapidly.64–66 Plasma concen-
trations should be obtained at 30, 45, and 60
minutes after administration of a dose.65, 66 Time
to the peak plasma concentration is longer with
ibuprofen tablets than with the liquid formulation.
Thus, plasma concentrations should be checked
at 1, 2, and 3 hours after administration with the
tablet form.61, 64–66 Given the limited available
data, no definitive dosing recommendations or
blood sampling guidelines can be provided for
ibuprofen chewable tablets.65 To optimize
therapy regardless of the form of ibuprofen
administered, peak plasma concentration must be
accurately determined to prevent misguided
dosage adjustments.
In a randomized, double-blind, placebo-
controlled trial, high-dose ibuprofen had
clinically beneficial effects on FEV1 and ideal
body weight (IBW).46 The study involved 85
patients, aged 5–39 years, with cystic fibrosis.
Patients were excluded if they had received
systemic corticosteroids, inhaled corticosteroids,
or nonsteroidal antiinflammatory drugs for more
than 2 weeks within 2 years of recruitment or
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inhaled cromolyn in the 6 months preceding the
study.  Of the 85 patients, 43 were randomly
assigned to placebo, 42 to ibuprofen tablets.
Food and pancreatic enzymes were withheld for
2 hours after each dose.  Ibuprofen 20–30 mg/kg
twice/day was the starting dosage.  This was
adjusted using pharmacokinetic analysis, with a
goal peak plasma concentration of 50–100 µg/ml.
Ibuprofen 20–30 mg/kg produced a peak
plasma ibuprofen concentration of 50–100 µg/ml
in most patients.  The dose range at which all
patients attained therapeutic concentrations was
16–32 mg/kg.  The dose was adjusted based on
pharmacokinetic analysis every 3 years, or sooner
if body weight increased 25%.  The primary
outcome measure, FEV1, declined 59% more
slowly in patients treated with ibuprofen than in
those assigned to placebo in the completed-
treatment analysis (p=0.03).  This benefit was
observed only in patients who were younger than
13 years at the start of treatment.  In this
subgroup, the rate of decline in FEV1 was
reduced by 65% (p=0.01) and 88% (p=0.005) in
the intent-to-treat and completed-treatment
analysis, respectively.  The FVC and forced
expiratory flow at 25–75% of FVC (FEF25–75)
also deteriorated, to a lesser extent, in ibuprofen-
treated patients at study completion (p<0.05).
Patients in the ibuprofen group maintained
their percent IBW throughout the 4-year study
period (p=0.01).  Compliance as assessed by tablet
count and blood monitoring was approximately
70% in each group.  Although ibuprofen effec-
tively improved FEV1 and percent IBW, the
results of this study must be interpreted with
caution.  The effect of ibuprofen on IBW was
most pronounced in the younger patients (5–13
yrs), and the improved FEV1 was observed only
in this group.  Since the information representing
these younger patients was a post hoc analysis
involving only 36 patients, further studies are
needed to determine the clinical importance of
these findings in this age group.
In healthy children, intermittent ibuprofen in
recommended dosages is associated with minimal
risk for gastrointestinal bleeding and nephro-
toxicity.67 Since higher ibuprofen dosages have
increased the risk for gastrointestinal adverse
effects, one might expect high-dose ibuprofen to
be poorly tolerated by patients with cystic
fibrosis.68 Neither a randomized, double-blind,
placebo-controlled trial of 85 patients nor a
retrospective review of 1354 patients prescribed
an initial dosage of ibuprofen 20–30 mg/kg
twice/day reported a significant increase in the
risk of gastrointestinal toxicity in children with
cystic fibrosis.46, 69 However, safety data from the
randomized trial were derived from a small
patient pool, with only 17 patients aged 5–13
years, the age group in which ibuprofen has had
the most pronounced benefit.46 Indeed,
anecdotal evidence and clinical experience with
high-dose ibuprofen suggest that this regimen is
not without gastrointestinal adverse effects.70
Risk of renal toxicity is a second concern
associated with ibuprofen therapy.  Studies have
not evaluated the effects of high-dose ibuprofen
on renal function in patients with cystic fibrosis.
However, an increased risk for renal toxicity has
been reported when this agent is used with intra-
venous aminoglycosides.71, 72 Ibuprofen adminis-
tration can be interrupted during aminoglycoside
therapy without producing a rebound increase in
pulmonary inflammation, and this practice is
recommended.60 Data concerning safety and
efficacy after long-term therapy with high-dose
ibuprofen are lacking.
Based on the studies described, ibuprofen
therapy improves maintenance of percent IBW
and slows the decline of lung function when
treatment is begun in children with cystic
fibrosis, aged 5–13 years, who have a predicted
FEV1 of 60% or greater.46 Although data directly
assessing the effect of ibuprofen on long-term
survival in patients with cystic fibrosis are
lacking, FEV1 and percent IBW are predictors of
mortality.73 The recommended initial dosage is
ibuprofen 20–30 mg/kg twice/day, titrated as
needed to a dosage that produces a peak plasma
concentration of 50–100 µg/ml based on pharmaco-
kinetic monitoring.
Patients or caregivers should be instructed to
separate the administration time of ibuprofen and
pancreatic enzymes by at least 2 hours and to
administer the ibuprofen on an empty stomach, if
tolerated, to allow optimal absorption.46 To
ensure that therapeutic concentrations are
maintained with prolonged treatment, pharmaco-
kinetic analysis should be performed every 3
years or with body weight increases of 25% or
more.  The need for periodic pharmacotherapeutic
monitoring and the lack of adequate safety data
in patients aged 5–13 years when treated with
high-dose ibuprofen have limited the routine
therapeutic use of this agent in children with
cystic fibrosis.
Cyclooxygenase-2 inhibitors, such as celecoxib,
rofecoxib, and valdecoxib, are often better
tolerated than ibuprofen.74–76 However, the
antiinflammatory mechanism of ibuprofen in
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cystic fibrosis differs from cyclooxygenase
inhibition.48–59 Treatment with cyclooxygenase-2
inhibitors in healthy children or in children with
cystic fibrosis has not been evaluated.
Azithromycin
Azithromycin is a macrolide commonly used
for its antibacterial activity in both children and
adults.  It is approved for treatment of acute otitis
media and community-acquired pneumonia in
patients older than 6 months and for treatment of
pharyngitis or tonsillitis in those aged 2 years or
older.77 Azithromycin has a long tissue half-life
and accumulates in the sputum and lungs of
treated patients.78 The potential role of azithro-
mycin in cystic fibrosis is extrapolated from
experience with diffuse panbronchiolitis, a
respiratory disease similar to cystic fibrosis.  In
patients with diffuse panbronchiolitis, long-term
erythromycin therapy improved both symptoms
and survival.79, 80
Azithromycin has been evaluated as a treatment
option for patients with cystic fibrosis for its
antiinflammatory properties.81 The precise
mechanism through which azithromycin exerts
these effects has not been elucidated (Figure
2).82–99 Antimicrobial classes typically used in the
treatment of acute cystic fibrosis exacerbations,
such as third-generation cephalosporins, amino-
glycosides, and fluoroquinolones, do not appear
to exert any significant direct antiinflammatory
action and have not been included in this review.100
Treatment with either erythromycin or
clarithromycin has not been beneficial in cystic
fibrosis.101 Six trials have evaluated the effects of
azithromycin in children and adults with cystic
fibrosis (Table 2).102–107 Of the three randomized,
placebo-controlled trials conducted, two involved
patients younger than 18 years.106, 107 Although a
benefit with azithromycin was observed in both
of these studies, the more recent one provides the
most compelling evidence of therapeutic
improvement.107
In a randomized, double-blind, placebo-
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Figure 2. Proposed antiinflammatory mechanisms of macrolide antibiotics.  The precise mechanism by which azithromycin
mitigates inflammation is unknown, but it affects neutrophils through mediation of apoptosis, migration, chemotactic activity,
and phagocytic function.  Azithromycin is an indirect antioxidant and may prevent lung damage through this function.
Therapy with this agent has inhibited production of nitric oxide, prostaglandin E2, and proinflammatory cytokines interleukin
(IL)-8, IL-1a, and tumor necrosis factor (TNF)-a. Azithromycin may also downregulate growth-related oncogene-a as well as
soluble vascular cell adhesion molecule (SVCAM)-1.  Reduced sputum viscoelasticity and improved mucociliary and cough
transportability of airway secretions has been noted.  Antagonism of the virulence of Pseudomonas aeruginosa has been proposed
as a mechanism, an effect mediated through a decrease in airway adherence, inhibition of production of various exoproducts,
and interference with Pseudomonas mucoid-alginate biofilm formation.  In addition, it may affect Pseudomonas aeruginosa’s
viability directly despite subinhibitory minimum inhibitory concentrations.  Restoration of the cystic fibrosis transmembrane
conductance regulator (CFTR) chloride channel is an additional possible mechanism.  X = mitigation of adverse effect.  (From
references 82–99.)
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controlled study involving 60 adults with cystic
fibrosis, treatment with azithromycin led to an
improvement in total quality of life (p=0.035), a
reduction in antibiotic therapy associated with
acute respiratory exacerbations (p<0.037), and a
slowed rate of decline in predicted FEV1
(p=0.047) and FVC (p=0.001).105 This benefit
was observed despite baseline patient
characteristics indicating the treatment group
had less lung function than the placebo group
(mean FEV1 50.9% vs 62.3%, mean FVC 67.3%
vs 77.5%).  The treatment group also was shorter,
on average, and weighed less than the placebo
group.  However, outcome changes in lung
function were small, indicating maintenance
rather than improvement.
In the first trial involving patients younger
than 18 years with cystic fibrosis, pulmonary
function was only modestly affected after a 6-
month course of azithromycin.106 This study—a
15-month, prospective, randomized, double-
blind, placebo-controlled, crossover trial—
included 41 children (18 boys, 23 girls) aged
8–18 years, with a median FEV1 of 61% (range
33–80%).  A history of chronic P. aeruginosa
colonization was not a specific entry criterion.
Exclusion criteria were liver disease, hearing
impairment, Burkholderia cepacia colonization,
previous organ transplantation, treatment with
macrolide antibiotics or oral corticosteroids for
more than 14 days, or treatment with dornase
alfa begun within 2 months of enrollment.
Azithromycin dosage was based on weight;
patients weighing 40 kg or less received 250 mg
once/day; those weighing more than 40 kg
received 500 mg once/day.  A clinically significant
change in the primary outcome measure, FEV1,
and the secondary outcome measures, FVC and
FEF25–75, was defined as a change of more or less
than 13%, 13%, and 20%, respectively.  At every
time point during treatment, mean FEV1, mean
FVC, and mean FEF25–75 were higher in the
azithromycin-treated patients than in the placebo
patients.  However, the median relative difference
in predicted FEV1 between azithromycin and
placebo was only 5.4% (p>0.05).  Improvement
in FEV1 greater than 13% was noted in 13 of 41
patients, whereas deterioration of more than 13%
was observed in five (p=0.059).  The median
relative difference in predicted FVC and FEF25–75
between the two groups was 3.9% and 11.4%,
respectively (p>0.05).  The results of this study
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Table 2.  Studies of Azithromycin Therapy in Patients with Cystic Fibrosis
Age Range, Treatment Change in FEV1, Adverse
No. of Mean, Median Duration FVC, FEF25–75 Drug
Study Design Patients (yrs) Azithromycin Dosage (mo) (% increase) Reactions
OL102 7 6–17, NR Median 7.2 FEV1: 11.0a NS
12, NR FVC: 11.3a
M, PC103 36 NR, 250 mg q.d. Mean 9.4 FEV1: 2.2b NS
NR, NR FVC: 5.7c
Observational104 14 NR, 250 mg q.o.d.d Mean 22.3 FEV1: 5.8b NS
24, NR FVC: 4.8e
FEF25–75: 6.5a
R, DB, PC105 60 18–44, 250 mg q.d. 3 FEV1: 3.0a
28, NR FVC: 3.8a
R, DB, PC, CO106 41 8–18, 250 mg q.d. (ABW ≤ 40 kg) 6 FEV1: 5.4e NS
NR, 14 500 mg q.d. (ABW > 40 kg) FVC: 3.9e
FEF25–75: 11.4e
R, DB, PC107 185 6–Adult, 250 mg MWF (ABW < 40 kg) 6 FEV1: 4.4c Nausea,
20, NR 500 mg MWF (ABW ≥ 40 kg) FVC: 3.7c diarrhea,
wheezingf
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FEF25–75 = forced expiratory flow at 25–75% of FVC; OL = open-
label; M = matched; PC = placebo controlled; CO = crossover; NR = not reported; NS = no significant difference compared with placebo; ABW =
actual body weight; MWF = Monday, Wednesday, and Friday.
ap<0.05 vs baseline.
bp=0.05 vs placebo.
cp<0.01 vs placebo.
dAdjusted to 250 mg/day in 8 of 14 patients.
ep>0.05.
fp<0.05 vs placebo.
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suggest that azithromycin treatment in children
and adolescents may exert clinically important
beneficial effects on pulmonary function in
approximately 33% of patients but may result in
worsening lung function in approximately
10–20% of patients.
The second study involving patients younger
than 18 years was a randomized, controlled study
in 185 patients aged 6 years or older with a
history of chronic P. aeruginosa colonization and
a predicted FEV1 of 30% or more.107 Of the 185
patients, 15 (average body weight < 40 kg)
received azithromycin 250 mg 3 times/week, 72
(average body weight ≥ 40 kg) azithromycin 500
mg 3 times/week, and 98 placebo.  Study
exclusion criteria were a history of B. cepacia or
nontuberculosis mycobacteria within 2 years of
screening, active liver disease, therapy with
intravenous or oral antibiotics within 14 days of
screening, therapy with a corticosteroid 20 mg or
more within 30 days of screening, and therapy
with inhaled tobramycin, dornase alfa, or high-
dose ibuprofen begun within 60 days of screening.
Use of dornase alfa and inhaled tobramycin
were similar in the treatment and placebo groups.
In the azithromycin group (both dosage groups)
nine patients were 6–12 years of age, 35 were
13–18 years, and 43 were older than 18 years.
The primary end point, relative change in FEV1,
was 6.2% in favor of azithromycin.  This was
depicted through a 4.4% improvement in the
azithromycin group and a decline of 1.8% in the
placebo group (p=0.001).  The response was
observed at day 28 and persisted until the end of
treatment.
Four weeks after azithromycin discontinuation,
FEV1 returned to nearly baseline percentages,
indicating the need for prolonged therapy to
maintain beneficial effects.  Predicted FVC
improved 3.7% in the azithromycin group but
declined 1.3% in the placebo group (p=0.002).
The rate of weight gain was higher in the
azithromycin-treated patients, who gained an
average of 0.7 kg more than those treated with
placebo (p=0.02).  Azithromycin treatment
resulted in significantly fewer respiratory
exacerbations (p=0.03) and was associated with
fewer hospitalizations (p=0.05).  Based on the
cystic fibrosis quality-of-life questionnaire,
physical functioning improved (p=0.05) but not
total quality of life (p=0.35).  This study reported
improvement in two predictors of mortality in
patients with cystic fibrosis—pulmonary function
and nutritional status—which suggests that
azithromycin may be of benefit in children with
this disease.
Clinical experience suggests that azithromycin
is better tolerated than other macrolide anti-
biotics.  Two placebo-controlled studies reported
that azithromycin treatment produced no adverse
effects in children or adults with cystic fibrosis.105,
106 In a third study with safety as a primary end
point, most adverse events were of mild-to-
moderate intensity.107 In azithromycin and
placebo groups, nausea (33% vs 16%), diarrhea
(23% vs 8%) and wheezing (17% vs 4%)
occurred more frequently in azithromycin-treated
patients (p≤0.01).  Increased mobilization of
respiratory tract secretions was believed to have
caused the increased wheezing.
Staphylococcus aureus colonization often occurs
at an early age in children with cystic fibrosis.108
An increased risk of selecting macrolide-resistant
staphylococcal species after azithromycin therapy
has been observed in patients with cystic fibrosis.109,
110 Since S. aureus is rarely a significant cystic
fibrosis pathogen in adolescents or adults, the
clinical implications of this finding are debatable.
Nontuberculosis mycobacteria is a second
potential respiratory pathogen in cystic fibrosis.
Colonization occurs in approximately 13% of
patients with cystic fibrosis, and prevalence
increases with age.111, 112 Although nontuberculosis
mycobacteria does not appear to have short-term
adverse effects on lung function in patients with
cystic fibrosis, effects on long-term outcome
cannot be ruled out.112 To minimize the risk for
selection of macrolide-resistant strains, physicians
are advised to screen for nontuberculosis
mycobacteria in patients with cystic fibrosis
before the start of azithromycin treatment and
then every 6 months.113 Azithromycin has not
increased the risk of bacterial resistance in
controlled studies involving patients with cystic
fibrosis treated for up to 6 months.105–107
Azithromycin has been implicated in fewer
drug-drug interactions than other macrolide
antibiotics114 but has had a strong inhibitory
effect on the actions of dornase alfa in vitro,
possibly by binding to human DNA and/or to
dornase alfa itself.115 The suggested interaction
between azithromycin and dornase alfa was
observed clinically in one randomized controlled
study.106 However, a subsequent study reported a
benefit in lung function associated with azithro-
mycin therapy even though 75% of patients in
the active treatment group were concomitantly
treated with dornase alfa.107
Azithromycin appears to be a well-tolerated
and clinically efficacious antiinflammatory
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treatment modality for maintenance of lung
function in children and adults with cystic
fibrosis.105–107 Most experience with azithromycin
has been with patients older than 13 years with a
history of chronic P. aeruginosa colonization; it
has not been studied in children younger than 6
years.  Azithromycin 250 mg 3 times/week in
patients weighing less than 40 kg and 500 mg 3
times/week in those weighing 40 kg or more may
be recommended in patients aged 6 years or older
with chronic P. aeruginosa colonization.  Azithro-
mycin may benefit patients without a docu-
mented history of P. aeruginosa with suspected
infection, although supporting literature is
lacking.
The beneficial effects of azithromycin in
patients with cystic fibrosis are generally
observed as early as 1 month after the start of
treatment but may be delayed for 4–6 months in
some patients.106, 107 Both caregivers and patients
should be informed of this variability in response
time.  Azithromycin therapy for up to 6 months
appears to be safe; nausea, diarrhea, and
wheezing are the predominant adverse effects.107
Continuing therapy seems necessary to maintain
the benefits associated with azithromycin
therapy.  An evaluation of the safety and efficacy
of this agent for treatment periods longer than 6
months is in progress.
Additional Therapies with Possible
Antiinflammatory Effects
Colchicine
Colchicine is an antiinflammatory agent
commonly prescribed for treatment of acute
attacks of gout.  A single open-label study
evaluated the potential benefits of colchicine in
patients with cystic fibrosis lung disease.116 The
study involved eight patients aged 5–28 years
(median 13.5 yrs) with end-stage cystic fibrosis
lung disease unresponsive to conventional
therapy. Treatment with colchicine 1 mg/day for
6–12 months (median 7 mo) was associated with
a subjective improvement in clinical status, a
significant decrease in antibiotic requirement,
and a potential improvement in pulmonary
function.
Among the eight patients studied, baseline
median predicted FEV1 and FVC, respectively,
were 62% (range 32–68%) and 54% (range
21–63%).  Colchicine treatment was associated
with a statistically significant decrease in median
days of antibiotic therapy, from 5 days/month to
1.2 days/month (p<0.05).  A significant improve-
ment in FEV1 and FVC was not observed;
however, the predicted FEV1 increased in six of
the eight patients treated.  Mild diarrhea was
reported in two patients, but colchicine treatment
was generally well tolerated.
The results of this study are compelling
enough to justify a large, randomized trial to
further evaluate the role of colchicine in patients
with cystic fibrosis lung disease.
Dornase alfa
Dornase alfa (recombinant human deoxy-
ribonucleic acid I) is a mucolytic agent that
improves mucociliary clearance through the
hydrolysis of extracellular deoxyribonucleic acid
in mucus of the cystic fibrosis airway.117 In
randomized trials, dornase alfa 2.5 mg/day
improved pulmonary function (increase in FEV1
3–16%) and decreased the risk of pulmonary
exacerbations.118–121 The response is variable, and
younger patients appear to respond better than
older patients.118, 121, 122 Treatment with dornase
alfa has been well tolerated for up to 2 years.118–121,
123 Although experience is limited regarding
administration of this agent to patients younger
than 5 years, it may be given to certain patients
deemed to be at significant risk of pulmonary
function deterioration and/or respiratory tract
infection.117 Upper airway irritation, characterized
by voice alteration and laryngitis, are the only
adverse effects reported more frequently with
dornase alfa than placebo.118
Airway inflammation may transiently increase
after the start of treatment with dornase alfa.124, 125
However, long-term therapy (3 yrs) appears to
mitigate inflammation by preventing the
progressive increase in total IL-8 sputum concen-
trations and free elastase activity that accompanies
cystic fibrosis lung disease.126 The antiinflam-
matory mechanism of dornase alfa is unclear.  It
may modulate inflammation by increasing the
clearance of neutrophil and neutrophil-degra-
dation product-rich secretions, or by decreasing
the frequency of pulmonary exacerbations, thus
limiting neutrophil infiltra-tion and the release of
neutrophil-degradation products.
Methotrexate
Methotrexate is a folic acid antagonist with
well-known antiinflammatory properties.
Although the antiinflammatory mechanism of
methotrexate in the cystic fibrosis lung is
unknown, the promotion of adenosine release
and/or the inhibition of transmethylation
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reactions may play a role.127 In a retrospective
study, clinical data were analyzed for five patients
with P. aeruginosa colonization and advanced
cystic fibrosis lung disease (predicted FEV1
25–65% at the start of treatment) unresponsive to
conventional therapy.128 The patients, aged
8.2–19.2 years, received oral methotrexate 10–20
mg/m2 once/week.  In the year preceding the start
of treatment, a median 10.5% decrease in FEV1
was observed (p<0.005).  After 1 year of treat-
ment, FEV1 increased by a median of 9% (range
2–15%, p<0.05).  In four of the five patients, IgG
levels decreased after initiation of methotrexate.
No severe adverse effects were observed.
These data suggest a potential benefit of
methotrexate in patients with advanced cystic
fibrosis lung disease.  However, the retrospective
study design and the small number of patients
involved precludes firm conclusions regarding
the safety or efficacy of methotrexate.  Controlled,
prospective studies are needed.
Montelukast
The selective cysteinyl leukotriene receptor
antagonist montelukast is indicated for treatment
of asthma and for relief of symptoms associated
with seasonal allergic rhinitis.129 Most patients
with cystic fibrosis have insufficient bronchial
lability to meet the diagnostic criteria for
asthma.130 As with asthma, however, patients
with cystic fibrosis have increased airway
cysteinyl leukotriene levels, which may
contribute to airway inflammation.131 Montelukast
has been studied as a treatment for patients with
cystic fibrosis.130, 132 The pharmacokinetic profile
of montelukast does not appear to be different in
patients with cystic fibrosis compared with the
general population.133 The dose and dosing
interval used to treat asthma may be extrapolated
to cystic fibrosis if similar target concentrations
are desired.
Two studies have evaluated the safety and
efficacy of montelukast in children and adults
with cystic fibrosis.130, 132 In an open-label,
observational study, 11 patients aged 16–44 years
(mean 25.9 yrs) with stable cystic fibrosis
(predicted FEV1 < 65%) were treated with
montelukast 10 mg at bedtime for 2 weeks.130 At
study conclusion, improvement was observed in
exercise tolerance (p=0.008) and morning peak
expiratory flow rate (p=0.003), but FEV1
remained unchanged.  Of interest, the patients
who improved the most were those who also had
positive Aspergillus serology results.
The second study was a randomized, double-
blind, placebo-controlled crossover trial
involving 16 patients (10 boys, 6 girls), aged
6–18 years (median 9.5 yrs), with mild cystic
fibrosis lung disease (predicted FEV1 70–
125%).132 Patients were treated with montelukast
5 mg (those aged 6–14 yrs) or 10 mg (those aged
> 14 yrs) once/day for 21 days in a crossover
design with a 4-week washout period.  Treatment
with montelukast was associated with reduced
eosinophilic inflammation, which was noted by a
decrease in serum eosinophil cationic protein
(p≤0.02) and eosinophil count (p≤0.027).
However, no significant change was noted in
clinical symptom score or lung function parameters
(FEV1, FVC).
Montelukast was well tolerated in both
studies.130, 132 Large, multicenter trials with
longer observation periods are needed to further
evaluate the safety and efficacy of montelukast as
an antiinflammatory agent in patients with cystic
fibrosis.  Montelukast 4 mg for patients aged 5
years or younger, 5 mg for those aged 6–14 years,
and 10 mg for those aged 15 years or older may
benefit patients with cystic fibrosis who also have
an asthmatic or allergic rhinitis component.
Pentoxifylline
Pentoxifylline, a nonspecific inhibitor of
phosphodiesterase, is believed to moderate
inflammation by increasing intracellular cyclic
adenosine 3′,5′-monophosphate.134 Pentoxifylline
blocks the inflammatory actions of tumor
necrosis factor (TNF)-a and affects cytokine
expression in a concentration-dependent man-
ner.135–146 Neutrophil function may be mitigated
through antagonism of these mediators.135, 147–150
Ex vivo, pentoxifylline has blocked the
destructive action of stimulated neutrophils in
isolated perfused lungs.147 Studies have
demonstrated the ability of pentoxifylline to
suppress neutrophil influx and ameliorate
pulmonary damage of primates infected with P.
aeruginosa148 and improve airway patency and
responsiveness in healthy volunteers treated with
an inhaled endotoxin.151 These findings led to
the investigation of pentoxifylline in patients
with cystic fibrosis.
In a randomized, double-blind, placebo-
controlled study, 16 patients with P. aeruginosa
colonization were treated with pentoxifylline or
placebo for 6 months.152 Nine patients aged
12–33 years (mean ± SD 8.2 ± 8.0 yrs) received
sustained-release pentoxifylline 400 mg 4
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times/day, mean dose 42.6 ± 4.2 mg/kg/day; seven
patients aged 12–32 years (mean ± SD 20.7 ± 7.0
yrs) received placebo.
At study conclusion, mean sputum elastase
concentration was significantly higher than at
baseline in the placebo group (p<0.05).
Concentrations were decreased in two of the nine
patients in the treatment group, but were similar
to those at baseline in the remaining seven
patients.  The FVC was improved in four patients
receiving pentoxifylline versus none in the
placebo group.  Mean FVC declined 7.2% and
0.8% in the placebo and treatment groups,
respectively (p=0.33).  Values for FEV1 and
FEF25–75 also were not significantly different
between the two groups.  Of the seven placebo
patients, four had a pulmonary exacerbation
requiring hospitalization for antibiotic treatment,
whereas only one of the nine pentoxifylline-
treated patients was hospitalized for treatment
(p=0.077).
This study suggests a potential role for
pentoxifylline in patients with cystic fibrosis.
Larger, randomized trials need be conducted in
both children and adults with cystic fibrosis
before treatment with this agent can be
recommended.  However, even if further studies
suggest a benefit, compliance with a 4-times/day
regimen would likely be difficult.
Nutritional Supplements
In patients with cystic fibrosis, the lungs are
exposed to extensive oxidative stress, an effect
that may result from a decrease in antioxidant
defenses.14, 15 The low plasma levels of anti-
oxidants may result from an increase in turnover
or metabolism of these substances.16 Supple-
mentation could correct this imbalance and thus
possibly attenuate lung inflammation.
b-Carotene
Plasma levels of b-carotene are significantly
lower in patients with cystic fibrosis than in
healthy controls, and the plasma level of b-
carotene is inversely correlated with IgG levels.16,
153–161 Together, this suggests a possible relation-
ship between b-carotene deficiency and pulmonary
inflammation.16 Improving plasma b-carotene
concentrations with supplementation has been
associated with improved pulmonary function
and a reduced rate of exacerbations.159, 160, 162
Supplementation with b-carotene 0.5–1.0
mg/kg can correct the deficiency commonly
observed in patients with cystic fibrosis.154, 155,
157–161 Studies have indicated that nearly normal
concentrations of b-carotene were reached 3–4
weeks after the start of therapy and plateaued
thereafter.155, 157–159 Treatment with b-carotene
also has reduced malondialdehyde concentrations,
a mediator of pulmonary dysfunction.155–161, 163
Two controlled studies159, 160 evaluating the
clinical efficacy of b-carotene supplementation in
cystic fibrosis were conducted in a total of 48
patients (mean age 11.7 yrs160 and 12.8 yrs159).
In both studies, patients were treated for 12
weeks with b-carotene 1 mg/kg, to a maximum
dosage of 50 mg/day.  Pulmonary exacerbations,
depicted as the number of days patients were
treated with antibiotics, were significantly
reduced in both studies (p<0.05).  In addition,
predicted FEV1—but not predicted FVC—was
improved in the first study’s younger patients.159
This benefit was not statistically significant, but
the improvement in pulmonary function was
correlated with b-carotene concentrations.  The
second study demonstrated no improvement in
pulmonary function.160 Data assessing the effect
of b-carotene on pulmonary function are conflicting.
Further studies are needed to determine
definitively the effect of this supplement on
pulmonary function because these two studies
were inadequately powered to detect a difference
if one existed.  Therapy with b-carotene 0.5–1
mg/kg/day, to a maximum dosage of 50 mg/day,
appears to be well tolerated.155, 159, 160
Essential Fatty Acids
Patients with cystic fibrosis are often deficient
in essential fatty acids.  This deficiency may
result from innate abnormalities in fatty acid
metabolism.164–167 Plasma omega-3 fatty acid
concentrations have correlated with pulmonary
function in cystic fibrosis.168 These fatty acids
inhibit generation of leukotriene B4 by neutro-
phils and may suppress the production of IL-1
and TNF-a.24
A short-term benefit has been observed after
intense supplementation with intravenous fatty
acids.169 However, parenteral therapy does not
seem to offer substantial clinical benefit, and
addition of routine intravenous therapy may add
undue psychological stress to treated patients.169,
170 Orally administered omega-3 fatty acids in the
form of fish oil may mitigate lung damage in
patients with cystic fibrosis.  Fish oil contains the
omega-3 fatty acids eicosapentaenoic acid and
docosahexaenoic acid; both possess antiinflam-
matory properties.  Several studies have demon-
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strated the feasibility of correcting fatty acid
deficiency and pancreatic insufficiency through
dietary fish oil supplementation in patients with
cystic fibrosis.171–174 Decreased production of
leukotriene B4 in the airways, with a subsequent
decrease in exposure of leukotriene B4 to
circulating neutrophils, has been suggested by
several studies as the mechanism for this
potential clinical benefit of fish oil in patients
with cystic fibrosis.167, 173, 175, 176
Two studies observed that treatment with fish
oil was associated with beneficial effects on
pulmonary function.167, 175 The first study, a
randomized, double-blind, placebo-controlled
trial, involved 16 patients with cystic fibrosis and
colonized with P. aeruginosa.175 The patients,
aged 12–26 years (median 17 yrs), were treated
with a 6-week course of fish oil capsules
providing 2.7 g/day of eicosapentaenoic acid.
Treatment resulted in a significant reduction in
sputum volume (p=0.015) and an improved
Shwachman score (p=0.034), FEV1 (p=0.006),
and vital capacity (p=0.011) compared with
placebo.
The second study involved 30 patients with
cystic fibrosis, aged 0.8–24.0 years (mean 12.4
yrs), with P. aeruginosa colonization and
pancreatic insufficiency.167 These patients were
treated with omega-3 fatty acids in the form of
fish oil in a mean daily dose containing 1.28 g of
eicosapentaenoic acid and 0.93 g of docosa-
hexaenoic acid.  After 8 months of supplemen-
tation, a small improvement was observed in
FEV1 (p<0.05) and in number of days of anti-
biotic treatment (p<0.05).
Fish oil is a relatively benign therapy when
administered to patients with cystic fibrosis.
Gastrointestinal symptoms are the most commonly
reported adverse effects; eructation, diarrhea, and
steatorrhea often necessitate an increased dosage
of pancreatic enzymes.172, 173, 175 Persistence of
these gastrointestinal symptoms, or the need for
higher dosages of enzymes than recommended,
may limit the utility of fish oil therapy in certain
patients.  Elevations of alanine aminotransferase
may also occur with supple-mentation with
omega-3 fatty acids.177 Liver function tests
should be monitored before treatment with fish
oil and as indicated during treatment.
Future Directions
In healthy individuals, the epithelial surface of
the lung is protected from the destructive action
of neutrophil elastase by two antiproteases:  a1-
antitrypsin and secretory leukoprotease inhibitor
(SLPI).9, 18, 19 The lower respiratory tract is
protected predominantly by a1-antitrypsin,
whereas SLPI provides the major anti–neutrophil
elastase protective screen at the epithelial surface
of the upper airways.19, 178 Although present in
normal concentrations, a1-antitrypsin and SLPI
are overwhelmed by neutrophil elastase in the
cystic fibrosis lung at an early age.9, 17–19 Active
neutrophil elastase is thus allowed to injure the
lung continuously, increasing secretion of mucus;
enhancing chemoattraction; stimulating produc-
tion of chemoattractants, such as IL-8, IL-6, and
leukotriene B4; and impairing opsonization and
the ability of the host to eliminate bacterial
pathogens, such as P. aeruginosa.18
Pharmacologic replacement of active anti-
proteases may be a novel therapeutic approach to
reduce the neutrophil elastase burden on the
respiratory epithelial surface in patients with
cystic fibrosis, thus ameliorating inherent
inflammatory actions.  The potential utility of
both SLPI and a1-antitrypsin in patients with
cystic fibrosis lung disease have been investi-
gated.17, 178–186
In patients with cystic fibrosis, inhalation of
recombinant (r) SLPI 100 mg every 12 hours
effectively increases epithelial lining fluid SLPI
and decreases epithelial lining fluid neutrophil
elastase and IL-8 concentrations.180, 181 The
increase in anti–neutrophil elastase capacity is
immediate and coincides with the rise in
epithelial lining fluid SLPI concentrations,
whereas the decrease in epithelial lining fluid
neutrophil elastase concentrations correlates with
the reduction in IL-8.180 Hence, suppressing
neutrophil elastase, a stimulus for IL-8 produc-
tion, which decreases neutrophil chemoattraction
to the lung and further lessens neutrophil
elastase concentrations, may mitigate lung
damage.  In addition to its effects on neutrophil
elastase, rSLPI also raises epithelial lining fluid
concentrations of the antioxidant glutathione,
which are often lower than normal in patients
with cystic fibrosis.182, 187 The subsequent
increase in antioxidant capacity of the epithelial
lining fluid is delayed for 24 hours after
inhalation.182
Treatment with rSLPI 100 mg every 12 hours
was administered to 45 adults (mean ± SD age 27
± 2 yrs) with cystic fibrosis for 7 days without
adverse effects.180, 181 Tissue concentrations of
rSLPI did not accumulate.181 Because the
imbalance of protease and oxidant constitutes a
major component of inflammation in cystic
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fibrosis lung disease, rSLPI may provide a dual
benefit.  However, rSLPI does not distribute well
to poorly ventilated and highly inflamed areas of
the lung.188 Therefore, although functional lung
tissue may be protected, inhaled rSLPI may be of
minimal benefit in patients with severe lung
disease.  Controlled studies are needed to assess
the safety and efficacy of rSLPI for pulmonary
function in patients with mild-to-moderate cystic
fibrosis lung disease.
The antiprotease a1-antitrypsin increases
epithelial lining fluid a1-antitrypsin concen-
trations; suppresses active neutrophil elastase,
increasing the anti–neutrophil elastase capacity;
reduces proteolysis; and reverses the ability of
respiratory epithelial lining fluid to interfere with
neutrophil killing of P. aeruginosa.184, 185 In
contrast to rSLPI, a1-antitrypsin does not
increase epithelial lining fluid glutathione levels
and thus has no direct antioxidant activity.
Inhaled a1-antitrypsin distributes to the distal
air spaces of the lung.189, 190 In a study of 26
patients with cystic fibrosis, a1-antitrypsin 100,
250, and 350 mg twice/day significantly
decreased neutrophil elastase activity.186 A trend
toward greater elastase inhibition was noted with
higher dosages.  Treatment has also been
associated with reduced proteolysis, but no
benefit in lung function has been observed.185
Inhaled a1-antitrypsin has been well tolerated.186
The effect of a1-antitrypsin on lung function and
progression of lung damage in patients with
cystic fibrosis is unknown.
The utility of inhaled recombinant human
monocyte and neutrophil elastase inhibitor, the
oral antiproteases L-658,758, DMP 777, ICI
200,355, and chemically modified tetracyclines is
under investigation.1, 191–196 Initial in vitro and
animal data are intriguing, and further studies
investigating the role of these anti–neutrophil
elastase agents are warranted.  The host defense
of a patient with cystic fibrosis lung disease may
be augmented through administration of IL-10.197
The use of a recombinant IL-10 preparation is
under investigation.
Conclusion
Inflammation is a major component of the
vicious cycle characterizing cystic fibrosis pul-
monary disease.  If untreated, this inflam-matory
process irreversibly damages the airways, leading
to bronchiectasis and ultimately respiratory
failure.  Most morbidity and nearly all mortality
in patients with cystic fibrosis are associated with
pulmonary disease.  Thus, interrupting the cycle
of obstruction, infection, and inflammation with
antiinflammatory agents may have a positive
impact on disease progression.
Investigators have observed that pulmonary
inflammation can be mitigated pharmacologically
by drugs and supplements that affect the function
or migration of neutrophils, modify the activity
of proinflammatory and antiinflammatory
cytokines and chemokines, antagonize the viru-
lence of bacteria such as P. aeruginosa, improve
the oxidant-antioxidant and protease-antiprotease
imbalance, or possibly directly affect the cystic
fibrosis transmembrane conductance regulator
gene.
Treatment with oral corticosteroids and
ibuprofen is associated with beneficial effects on
several disease parameters; however, oral
corticosteroid therapy is limited by adverse
effects.  Children with cystic fibrosis can be
treated with ibuprofen, assuming treatment is
begun when they are aged 5–13 years and the
clinician commits to evaluating patient toler-
ability and to monitoring plasma concentrations
routinely to ensure efficacy and minimize
toxicity.  Inhaled corticosteroids, though well
tolerated, do not appear to affect inflammation of
the cystic fibrosis airway to a great extent.  The
decision to administer inhaled corticosteroids in
children with cystic fibrosis should be made on a
patient-to-patient basis.
Azithromycin, which has been effective and
well tolerated, is the most promising anti-
inflammatory therapeutic agent for treatment of
cystic fibrosis pulmonary disease.  Therapy with
this agent can be recommended for children aged
6 years or older with P. aeruginosa colonization or
a suspected history of P. aeruginosa colonization.
The most appropriate patient age at which
antiinflammatory treatment should be started is a
topic of debate.  However, because the antiinflam-
matory therapies are preventive, younger patients
would be expected to benefit to a greater extent
than those in whom substantial lung damage has
already occurred.  Therefore, early initiation of
antiinflammatory therapy should be recommended.
Future studies should be directed toward
establishing the safety and efficacy of these
therapies in children younger than 5 years.
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